Malaysian Genomics Resource Centre Bhd (XKLS:0155) Beneish M-Score: -2.50 (As of Jun. 24, 2026)


XKLS:0155 Malaysian Genomics Resource Centre Bhd XKLS:0155
47 GF Score
Price RM0.27
GF Value RM0.30
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Malaysian Genomics Resource Centre Bhd Beneish M-Score?

Malaysian Genomics Resource Centre Bhd XKLS:0155 +1.89% 47 Beneish M-Score is -2.50 as of Jun. 24, 2026. GuruFocus rates XKLS:0155 with a GF Score™ of 47/100 and a GF Value™ of RM0.30 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 195 Medical Diagnostics & Research companies, Malaysian Genomics Resource Centre Bhd ranks worse than 60% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.5 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Malaysian Genomics Resource Centre Bhd's Beneish M-Score or its related term are showing as below:

XKLS:0155' s Beneish M-Score Range Over the Past 10 Years
Min: -4.58   Med: -2.3   Max: 71.61
Current: -2.5

During the past 13 years, the highest Beneish M-Score of Malaysian Genomics Resource Centre Bhd was 71.61. The lowest was -4.58. And the median was -2.30.


Malaysian Genomics Resource Centre Bhd Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Malaysian Genomics Resource Centre Bhd's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Malaysian Genomics Resource Centre Bhd Beneish M-Score Chart

Malaysian Genomics Resource Centre Bhd Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.12 0.00 11.73 -3.90 -3.45

Malaysian Genomics Resource Centre Bhd Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.54 -3.27 -3.13 -3.45 -2.50

XKLS:0155 vs TMO, DHR, IDXX: Beneish M-Score Comparison

For the Diagnostics & Research subindustry, Malaysian Genomics Resource Centre Bhd's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Malaysian Genomics Resource Centre Bhd Beneish M-Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Malaysian Genomics Resource Centre Bhd's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Malaysian Genomics Resource Centre Bhd's Beneish M-Score falls into.


XKLS:0155
47GF Score
Malaysian Genomics Resource Centre Bhd XKLS:0155
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Malaysian Genomics Resource Centre Bhd Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Malaysian Genomics Resource Centre Bhd for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.4988+0.528 * 0.8935+0.404 * 0.9372+0.892 * 1.7396+0.115 * 0.8253
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.4646+4.679 * -0.067863-0.327 * 0.6585
=-2.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was RM8.12 Mil.
Revenue was 2.654 + 2.394 + 2.484 + 1.796 = RM9.33 Mil.
Gross Profit was 2.386 + 1.449 + 1.628 + 1.188 = RM6.65 Mil.
Total Current Assets was RM12.58 Mil.
Total Assets was RM21.40 Mil.
Property, Plant and Equipment(Net PPE) was RM2.97 Mil.
Depreciation, Depletion and Amortization(DDA) was RM1.44 Mil.
Selling, General, & Admin. Expense(SGA) was RM5.67 Mil.
Total Current Liabilities was RM2.27 Mil.
Long-Term Debt & Capital Lease Obligation was RM0.84 Mil.
Net Income was 1.14 + -1.653 + 0.389 + -0.37 = RM-0.49 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = RM0.00 Mil.
Cash Flow from Operations was 0.098 + 0.513 + 0.573 + -0.226 = RM0.96 Mil.
Total Receivables was RM9.36 Mil.
Revenue was 1.349 + 1.309 + 1.401 + 1.303 = RM5.36 Mil.
Gross Profit was 0.94 + 1.052 + 0.887 + 0.537 = RM3.42 Mil.
Total Current Assets was RM11.11 Mil.
Total Assets was RM21.50 Mil.
Property, Plant and Equipment(Net PPE) was RM4.12 Mil.
Depreciation, Depletion and Amortization(DDA) was RM1.52 Mil.
Selling, General, & Admin. Expense(SGA) was RM7.01 Mil.
Total Current Liabilities was RM3.60 Mil.
Long-Term Debt & Capital Lease Obligation was RM1.15 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(8.119 / 9.328) / (9.356 / 5.362)
=0.87039 / 1.744871
=0.4988

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(3.416 / 5.362) / (6.651 / 9.328)
=0.637076 / 0.713015
=0.8935

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (12.575 + 2.969) / 21.396) / (1 - (11.106 + 4.119) / 21.499)
=0.273509 / 0.291828
=0.9372

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=9.328 / 5.362
=1.7396

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.518 / (1.518 + 4.119)) / (1.438 / (1.438 + 2.969))
=0.269292 / 0.326299
=0.8253

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(5.667 / 9.328) / (7.012 / 5.362)
=0.607526 / 1.307721
=0.4646

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.842 + 2.273) / 21.396) / ((1.151 + 3.602) / 21.499)
=0.145588 / 0.22108
=0.6585

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-0.494 - 0 - 0.958) / 21.396
=-0.067863

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Malaysian Genomics Resource Centre Bhd has a M-score of -2.50 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.50 mean?
Malaysian Genomics Resource Centre Bhd (XKLS:0155) has a Beneish M-Score of -2.50 as of Jun. 24, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Malaysian Genomics Resource Centre Bhd and its competitors. According to the industry distribution chart, Malaysian Genomics Resource Centre Bhd ranks #117 out of 195 companies in the Medical Diagnostics & Research industry, placing it in the top 60%.
Is Malaysian Genomics Resource Centre Bhd's Beneish M-Score too high?
Malaysian Genomics Resource Centre Bhd's current Beneish M-Score is -2.50. Based on the distribution chart, Malaysian Genomics Resource Centre Bhd ranks #117 out of 195 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Malaysian Genomics Resource Centre Bhd has a GF Score™ of 47/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Malaysian Genomics Resource Centre Bhd's Beneish M-Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Malaysian Genomics Resource Centre Bhd ranks #117 out of 195 companies for Beneish M-Score. This places Malaysian Genomics Resource Centre Bhd in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Diagnostics & Research company?
A good Beneish M-Score depends on the Medical Diagnostics & Research industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Malaysian Genomics Resource Centre Bhd and its competitors. Malaysian Genomics Resource Centre Bhd's current Beneish M-Score is -2.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Malaysian Genomics Resource Centre Bhd stock overvalued right now?
Based on GuruFocus' analysis, Malaysian Genomics Resource Centre Bhd (XKLS:0155) is currently considered Modestly Undervalued. The stock's GF Value™ is RM0.30, compared to a current price of RM0.27 — trading 10% below its estimated fair value. The current Beneish M-Score is -2.50. Malaysian Genomics Resource Centre Bhd's overall GF Score™ is 47/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Malaysian Genomics Resource Centre Bhd (XKLS:0155), the current Beneish M-Score is -2.50 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Malaysian Genomics Resource Centre Bhd (XKLS:0155) Overvalued in 2026?

Based on GuruFocus' analysis, Malaysian Genomics Resource Centre Bhd stock appears to be undervalued. The current stock price of RM0.27 is trading 10% below its estimated GF Value™ of RM0.30. GuruFocus considers Malaysian Genomics Resource Centre Bhd to be Modestly Undervalued.

Key valuation signals for XKLS:0155:

  • Beneish M-Score: -2.50
  • GF Value™: RM0.30 vs. price of RM0.27 (10% below fair value)
  • GF Score™: 47/100 with 2 warning signs

No single metric tells the full story. See the XKLS:0155 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Malaysian Genomics Resource Centre Bhd Business Description

Address Jalan Teknologi 3/6, 8F, Taman Sains Selangor 1, Kota Damansara (PJU5), Petaling Jaya, SGR, MYS, 47810
Malaysian Genomics Resource Centre Bhd is a Malaysia-based company. The company's principal activities include enabling personalized and precision medicine through genetics, genomics, immunotherapy, and biopharmaceutical services, as well as investment holding. It offers genome sequencing and analysis (GSA) services and genetic screening services (GSS). The group offerings include precision genetic screening, project-based analysis, and high-quality cell therapy and cosmeceutical products. The reportable segments of the Group derive their revenue from the provision of personalised and precision medicine through genetics, genomics, immunotherapy, and biopharmaceutical services within the healthcare segment.
47GF Score

Get the complete analysis for XKLS:0155

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

RM0.27
Price
RM0.30
GF Value